Reported about 11 hours ago
Pfizer Inc. (PFE), a leader in the global pharmaceutical industry, is enhancing its mRNA vaccine portfolio and focusing on oncology and hemophilia treatments. The company has reported promising Phase 3 results for its adaptive COVID-19 vaccine, which demonstrates its strength in evolving vaccine technologies. Additionally, Pfizer is making notable strides in cancer therapies, particularly with its combination treatment for bladder cancer and advancements in hemophilia care. Despite facing regulatory challenges, the company continues to invest heavily in research and development.
Source: YAHOO